NVCR vs. IART, ICUI, LMAT, NARI, TNDM, ATEC, IRTC, MDXG, ATRC, and PRCT
Should you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Integra LifeSciences (IART), ICU Medical (ICUI), LeMaitre Vascular (LMAT), Inari Medical (NARI), Tandem Diabetes Care (TNDM), Alphatec (ATEC), iRhythm Technologies (IRTC), MiMedx Group (MDXG), AtriCure (ATRC), and PROCEPT BioRobotics (PRCT). These companies are all part of the "surgical & medical instruments" industry.
Integra LifeSciences (NASDAQ:IART) and NovoCure (NASDAQ:NVCR) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability.
Integra LifeSciences presently has a consensus price target of $36.80, indicating a potential upside of 33.62%. NovoCure has a consensus price target of $30.88, indicating a potential upside of 40.40%. Given Integra LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe NovoCure is more favorable than Integra LifeSciences.
Integra LifeSciences has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.
84.8% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 3.1% of Integra LifeSciences shares are owned by company insiders. Comparatively, 6.3% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Integra LifeSciences had 2 more articles in the media than NovoCure. MarketBeat recorded 5 mentions for Integra LifeSciences and 3 mentions for NovoCure. Integra LifeSciences' average media sentiment score of 0.79 beat NovoCure's score of 0.69 indicating that NovoCure is being referred to more favorably in the news media.
Integra LifeSciences has a net margin of 2.63% compared to Integra LifeSciences' net margin of -36.67%. NovoCure's return on equity of 14.27% beat Integra LifeSciences' return on equity.
NovoCure received 31 more outperform votes than Integra LifeSciences when rated by MarketBeat users. Likewise, 63.71% of users gave NovoCure an outperform vote while only 57.90% of users gave Integra LifeSciences an outperform vote.
Integra LifeSciences has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.
Summary
Integra LifeSciences beats NovoCure on 10 of the 18 factors compared between the two stocks.
Get NovoCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovoCure Competitors List
Related Companies and Tools
